NEW YORK (GenomeWeb) – Appistry said today that it has signed a deal to include Personal Genome Diagnostics' CancerSelect panel in the recently released Appistry CloudDx genomics testing service.
Appistry launched the new service, which makes laboratory-developed tests from diagnostic test providers available to physicians across the US via the cloud, at the American Society of Clinical Oncology annual meeting this week in Chicago. PGDx, which offers cancer genome analyses to oncology researchers, drug developers, clinicians, and patients out of its CLIA lab, is one of the first organizations to offer its services through Appistry's new portal.
According to Appistry, its CloudDx service provides a single web dashboard for ordering and tracking the progress of tests while orchestrating a data flow between test providers and requesting physicians and hospitals. It added that the service ensures that data and physical samples are transferred and securely managed in accordance with HIPAA and CLIA guidelines.
"Making CancerSelect available through Appistry CloudDx will extend our reach, enabling our panel to be utilized more broadly by community physicians looking to provide the best diagnostic and treatment options to their patients," Antony Newton, chief commercial officer for Baltimore-based PGDx.
CancerSelect is a targeted cancer gene panel for the detection of genetic alterations in 120 well-characterized cancer genes, which are considered of clinical and biologic importance. The firm screens the genes using next-generation sequencing at "extremely high coverage to identify point mutations, copy number alterations, and translocations," according to PGDx's website.
Further terms of the agreement between Appistry and PGDx were not disclosed.